Related Experiment Videos
[Ovarian cancer (experience with 186 patients)]
A Torres Lobaton1, J M Matías Salvador, R Herrera
1Servico de Oncología, Hospital General de México.
Ginecologia Y Obstetricia De Mexico
|September 1, 1992
Summary
This study analyzed 186 ovarian carcinoma cases from 1981-1990. Treatment outcomes varied by stage, with stage III patients benefiting from chemotherapy when residual disease was minimal.
Area of Science:
- Gynecologic Oncology
- Clinical Oncology
- Epidemiology
Context:
- Retrospective analysis of 186 ovarian carcinoma cases treated between 1981 and 1990.
- Data collected from the Oncology Service at The General Hospital of Mexico.
- Review of epidemiological and clinical aspects alongside treatment results.
Purpose:
- To report on the experience with ovarian carcinoma treatment over a decade.
- To evaluate treatment efficacy based on clinical stage and residual disease.
- To identify prognostic factors and treatment outcomes in ovarian cancer patients.
Summary:
- Ovarian carcinoma staging distribution: Stage I (26.9%), Stage II (1.0%), Stage III (60.7%), Stage IV (11.2%).
- Overall, 73.6% of patients had follow-up, with 23.3% disease-free for 12-60 months.
- Stage I prognosis showed no significant difference across surgery, postoperative radiotherapy, or chemotherapy.
- Stage III patients achieved better outcomes with residual disease ≤2 cm, particularly with combination chemotherapy (cyclophosphamide plus adriamycin or cisplatin).
Impact:
- Highlights the importance of residual disease status in Stage III ovarian cancer management.
- Suggests combination chemotherapy may improve outcomes for advanced-stage ovarian cancer.
- Provides valuable data for understanding long-term disease control in ovarian carcinoma.